Vitiligo is an autoimmune skin disorder that can significantly affect the quality of life in patients. However, currenttreatment strategies such as phototherapy, topical glucocorticosteroids, or systemic immunosuppressants canbe helpful in vitiligo management, and treatments for disease stability which is the main challenge in vitiligomanagement. Novel therapeutic modalities have made promising advances in this regard. Molecular targetedtherapy to target Janus-activated kinase (JAK) such as Tofacitinib and Ruxolitinib in addition to the cell-basedtreatments are innovative therapeutic options, which are recently used for vitiligo treatment. Transplantation ofnon-cultured melanocytes-keratinocytes have been studied in Iran and phase one data published in 2010 on 10patients that continued on 300 patients as phase three in 2018. Cell Tech Pharmed™ Co. registered and appliedthis cell-based product, ReColorCell®, as a GMP certified by Iranian Food and Drug Administration (IR-FDA). On11th December 2021, ReColorCell® officially registered as the first cell-based product in the Iranian drug list (IDL).Currently, the post-market study of this product is ongoing.